Preclinical biodistribution and safety evaluation of human iPSC-derived dopaminergic neural progenitor cells for Parkinson’s disease
This study developed a novel method for determining biodistribution and differentiation <i>in vivo</i>, provided a strategy to evaluate the safety of iPSC derived DAPs, and showed their safety in mice. The data provides essential safety data for the clinical translation of DAPs and supports their phase I clinical trials in China and the United States.
Authors
- Ying Huang (ORCID: https://orcid.org/0000-0003-2288-8314)
- Lily Li (ORCID: https://orcid.org/0000-0001-9844-7692)
- Zhi Lin
- Hua Jiang
- Xiang Li
- Chao Qin
- Frank Zhu
- Lulu Li
- Xingchao Geng
- Qianqian Li
- Yiyang Mao
- Hairuo Wen
Institutions
- National Medical Products Administration (CN)
- National Institutes for Food and Drug Control (CN)
- Suzhou Industrial Park Vocational Technical College (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fcell.2025.1701748
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China